Core Viewpoint - INVO Fertility, Inc. announced a 1-for-3 reverse stock split to comply with Nasdaq's minimum bid price requirement, effective July 21, 2025 [1][3]. Group 1: Reverse Stock Split Details - The reverse stock split will convert every 3 shares of common stock into 1 share, rounding up any fractional shares [2]. - Post-split, the company will have approximately 928,272 shares issued and outstanding, with authorized shares adjusted to 1,388,888 [2]. Group 2: Company Overview - INVO Fertility is focused on expanding assisted reproductive technology (ART) care, operating fertility clinics, and distributing its proprietary INVOcell medical device [4]. - The INVOcell device allows fertilization and early embryo development to occur in vivo, offering a more natural and cost-effective alternative to traditional IVF [4].

Core Insights - INVO Fertility, Inc. is enhancing its fertility services through expanded clinical and embryology training support and improved pricing for its INVOcell technology, aiming to provide patient-centered care while expanding clinic operations [1][3][4] Company Overview - INVO Fertility focuses on the fertility market, operating two INVO Centers and one IVF clinic in the U.S., and aims to build, acquire, and operate more fertility clinics [6] - The company offers the INVOcell, the first FDA-cleared intravaginal culture system, which allows fertilization and early embryo development to occur within a woman's body, providing a more natural alternative to traditional IVF [2][6] Product and Technology - INVOcell delivers comparable pregnancy rates to conventional IVF while offering a more intimate and affordable experience for patients [2][8] - The company has secured a notice of allowance for a new patent from the U.S. Patent and Trademark Office, reinforcing its position as a technology innovator [4] Training and Support - INVO Fertility provides hands-on training and clinical support for embryologists and physicians to integrate the INVOcell solution into their practices [3] - The company is launching targeted educational campaigns to raise awareness of patient success rates with INVOcell, which are similar to those of conventional IVF [3] Market Positioning - INVOcell is positioned as an inclusive option for diverse family structures, including same-sex couples and single parents, and offers a streamlined lab workflow for clinics [8]

Core Insights - NewGenIvf Group Limited's subsidiary, NewGenDigital, has secured a strategic plot of land in Ras Al Khaimah, UAE, and is exploring the feasibility of issuing digital tokens tied to this plot as part of a blockchain asset digitization strategy [1][3] - The real estate project associated with the plot is projected to generate sales revenue exceeding US$400 million, indicating significant potential for financial returns [1][4] - The plot, measuring 110,400 sq. ft. with an estimated saleable area of approximately 527,750 sq. ft., is located in a prime beachfront area, benefiting from the region's economic growth and investor-friendly policies [2][4] Company Strategy - NewGenDigital aims to leverage Real World Asset (RWA) tokenization, which transforms physical assets like real estate into digital tokens, enhancing ownership management and liquidity [3] - The UAE's regulatory environment, including the establishment of the Ras Al Khaimah Digital Assets Oasis Free Zone and the Virtual Asset Regulatory Authority, supports NewGenDigital's blockchain initiatives [3] - The company's strategic move into the digital asset space aligns with its broader investment initiative of US$45 million in the UAE real estate market [1][3] Market Context - The Ras Al Khaimah region is poised for growth, particularly with the upcoming Wynn Al Marjan Island integrated resort set to open in early 2027, which is expected to further enhance the area's attractiveness for investment [2] - NewGenDigital's entry into the region is welcomed by local developers, indicating a collaborative environment for international brands and developers [4]

Core Viewpoint - INVO Fertility, Inc. has introduced Platelet-Rich Plasma (PRP) therapy at its Wisconsin Fertility Institute center, enhancing its fertility services and commitment to innovative patient care [1][3]. Group 1: PRP Therapy Overview - PRP therapy utilizes the body's growth factors to promote uterine lining growth and ovarian rejuvenation, potentially improving implantation rates and ovarian response [2]. - This treatment is particularly beneficial for women with specific fertility challenges, such as a thin uterine lining or diminished ovarian reserve, and serves as an alternative to egg donation or surrogacy [2]. Group 2: Company Strategy and Offerings - INVO Fertility focuses on expanding assisted reproductive technology (ART) care through building, acquiring, and operating fertility clinics, including INVO Centers that offer the intravaginal culture (IVC) procedure using the INVOcell medical device [4]. - The INVOcell device allows fertilization and early embryo development to occur in vivo, providing a more natural and affordable experience compared to traditional IVF, with comparable results at a lower cost [4].

Core Viewpoint - INVO Fertility, Inc. is urging shareholders to vote online for the upcoming annual meeting on June 25, 2025, with the Board recommending a "FOR" vote on all proposals to support the company's growth strategies [1][2]. Company Overview - INVO Fertility is focused on expanding assisted reproductive technology (ART) care, primarily through building, acquiring, and operating fertility clinics, including INVO Centers that utilize the INVOcell medical device [5][7]. - The company currently operates two INVO Centers and one IVF clinic in the United States, and it is engaged in the sale and distribution of INVOcell technology to third-party clinics [5][7]. Growth Strategies - The CEO highlighted a robust pipeline of potential transactions for complementary and revenue-generating services and technologies, aiming to leverage the company's public platform for favorable transactions [2]. - The company is focused on acquiring established, profitable fertility clinics and expanding its INVOcell technology to capitalize on favorable market trends and policy developments [2]. Voting Information - Shareholders of record as of May 21, 2025, are entitled to vote at the Annual Meeting, and various voting methods are available, including online, by mail, and by phone [3][6]. - The Annual Meeting will be conducted virtually, allowing shareholders to submit questions and vote online [4].

Core Viewpoint - INVO Fertility, Inc. is expanding its telehealth capabilities at the Wisconsin Fertility Institute to enhance access to fertility care for prospective parents, particularly in underserved areas [1][5]. Group 1: Telehealth Expansion - The telehealth platform allows patients to connect with fertility specialists from home, providing personalized assessments and treatment planning through secure virtual consultations [3][4]. - This initiative aims to break down geographic barriers, making expert fertility care more accessible and convenient for individuals and couples [4][5]. Group 2: Service Reach and Accessibility - The expansion is expected to significantly broaden the reach of Wisconsin Fertility Institute, especially for those in rural areas facing challenges in accessing specialized fertility care [5]. - The integration of telehealth with in-clinic procedures is designed to help families navigate the complexities of fertility treatment with greater confidence and ease [5]. Group 3: Company Overview - INVO Fertility focuses on expanding assisted reproductive technology (ART) care through the establishment and operation of fertility clinics, including the innovative INVOcell medical device [7]. - The company operates two INVO Centers and one IVF clinic in the U.S., and continues to distribute its INVOcell technology to third-party clinics [7].

Core Viewpoint - INVO Fertility, Inc. is expanding its telehealth capabilities at the Wisconsin Fertility Institute to enhance access to fertility care for prospective parents, particularly in underserved areas [1][5]. Group 1: Telehealth Expansion - The telehealth platform allows patients to connect with fertility specialists from home, providing personalized assessments and treatment planning through secure virtual consultations [3][4]. - This initiative aims to break down geographic barriers, making expert fertility care more accessible and convenient for individuals and couples [4][5]. Group 2: Service Reach and Accessibility - The expansion is expected to significantly broaden the reach of Wisconsin Fertility Institute, especially for those in rural areas facing challenges in accessing specialized fertility care [5]. - The integration of telehealth with in-clinic procedures is designed to help families navigate the complexities of fertility treatment with greater confidence and ease [5]. Group 3: Company Overview - INVO Fertility focuses on expanding assisted reproductive technology (ART) care through the establishment and operation of fertility clinics, including the innovative INVOcell medical device [7]. - The company operates two INVO Centers and one IVF clinic in the U.S., and continues to distribute its INVOcell technology to third-party clinics [7].

Core Insights - INVO Fertility, Inc. has announced that its Wisconsin Fertility Institute clinic has been recognized as one of America's Best Fertility Clinics for 2025 by Newsweek [1][2] - The ranking was developed in partnership with Statista and evaluated clinics based on criteria set by the CDC [2][5] - The CEO of INVO Fertility expressed pride in the recognition, attributing it to the dedication of the team in providing high-quality fertility care [2] Company Overview - INVO Fertility is focused on expanding access to assisted reproductive technology (ART) through the establishment, acquisition, and operation of fertility clinics [3] - The company operates two INVO Centers and one IVF clinic in the United States, and is engaged in the sale and distribution of its proprietary INVOcell technology [3] - The INVOcell device allows fertilization and early embryo development to occur in vivo, offering a more natural and affordable alternative to traditional IVF [3] Evaluation Criteria - The evaluation for the America's Best Fertility Clinics included quality metrics based on ART indicators published by the CDC [5] - A nationwide online survey was conducted involving reproductive endocrinologists, infertility specialists, and other medical professionals [5] - Accreditation data from various medical organizations and patient satisfaction data from Google reviews were also considered in the evaluation [5]

Core Insights - INVO Fertility, Inc. has announced that its Wisconsin Fertility Institute clinic has been recognized as one of America's Best Fertility Clinics for 2025 by Newsweek [1][2] - The ranking was developed in partnership with Statista and evaluated clinics based on criteria set by the CDC [2][5] - The CEO of INVO Fertility expressed pride in the recognition, attributing it to the dedication of the team in providing high-quality fertility care [2] Company Overview - INVO Fertility is focused on expanding access to assisted reproductive technology (ART) through the establishment, acquisition, and operation of fertility clinics [3] - The company operates two INVO Centers and one IVF clinic in the United States, and is engaged in the sale and distribution of its proprietary INVOcell technology [3] - The INVOcell device allows fertilization and early embryo development to occur in vivo, offering a more natural and affordable alternative to traditional IVF [3] Evaluation Criteria - The evaluation for the Best Fertility Clinics included quality metrics from ART, a nationwide survey of medical professionals, accreditation data from recognized bodies, and patient satisfaction based on Google reviews [5]

Core Insights - NewGen plans to invest US$45 million in the UAE real estate market, focusing on properties near the Wynn Al Marjan Island integrated resort, marking a diversification from its traditional IVF business operations [1][2] - The investment is driven by Ras Al Khaimah's strong economic growth, political stability, and significant infrastructure developments, which are expected to enhance property values [2][5] - NewGen is also considering additional investments in Abu Dhabi's real estate market, which offers stability and long-term growth potential [2][3] Investment Strategy - The company has engaged UAE-based business development manager Samira Aissani to lead property acquisition initiatives, leveraging her extensive experience in UAE real estate [3] - NewGen is in advanced discussions for strategic plot acquisitions in Ras Al Khaimah and has established partnerships with prominent UAE developers [3][4] - A term sheet has been executed with Enclave Capital LLC to raise an additional US$45 million to support the UAE real estate expansion [4] Market Potential - The Wynn Al Marjan Island integrated resort, a multi-billion dollar development set to open in early 2027, is expected to drive demand for real estate in Ras Al Khaimah [2] - The region's strategic location, with 31% of the world's population within four hours' flying time, along with favorable investment policies, creates an ideal environment for real estate appreciation [2] - NewGen's CEO expressed confidence that the investment will deliver substantial returns and establish a strong foundation for future growth [5]